|
| 37130596 | Remove barriers to clinical research for schedule 1 drugs with therapeutic potential. | BMJ | 2023 |
| 36087581 | Signaling snapshots of a serotonin receptor activated by the prototypical psychedelic LSD. | Neuron | 2022 |
| 35401275 | Entactogens: How the Name for a Novel Class of Psychoactive Agents Originated. | Front Psychiatry | 2022 |
| 35699130 | Preface to the special issue "Psychedelics and Neurochemistry". | J Neurochem | 2022 |
| 33285579 | The History of Psychedelics in Psychiatry. | Pharmacopsychiatry | 2021 |
| 34555409 | The effects of acute stress on attentional networks and working memory in females. | Physiol Behav | 2021 |
| 34151472 | Cannabinoid polymorphisms interact with plasma endocannabinoid levels to predict fear extinction learning. | Depress Anxiety | 2021 |
| 34340176 | BDNF genotype Val66Met interacts with acute plasma BDNF levels to predict fear extinction and recall. | Behav Res Ther | 2021 |
| 32398764 | Psilocybin: from ancient magic to modern medicine. | J Antibiot (Tokyo) | 2020 |
| 32946782 | Structure of a Hallucinogen-Activated Gq-Coupled 5-HT<sub>2A</sub> Serotonin Receptor. | Cell | 2020 |
| 30298278 | Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA). | Psychopharmacology (Berl) | 2019 |
| 30252437 | Understanding Central Nervous System Effects of Deliriant Hallucinogenic Drugs through Experimental Animal Models. | ACS Chem Neurosci | 2019 |
| 31303095 | Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. | J Psychopharmacol | 2019 |
| 31297368 | Sustained Release of Phosphates From Hydrogel Nanoparticles Suppresses Bacterial Collagenase and Biofilm Formation <i>in vitro</i>. | Front Bioeng Biotechnol | 2019 |
| 30443792 | Correction to: Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA). | Psychopharmacology (Berl) | 2019 |
| 28585392 | Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775). | Drug Test Anal | 2018 |
| 29991342 | Author's reply. | J Psychopharmacol | 2018 |
| 28401524 | Chemistry and Structure-Activity Relationships of Psychedelics. | Curr Top Behav Neurosci | 2018 |
| 29408722 | Is LSD toxic? | Forensic Sci Int | 2018 |
| 29461039 | Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD). | ACS Chem Neurosci | 2018 |
| 29095071 | N,N-dimethyltryptamine and the pineal gland: Separating fact from myth. | J Psychopharmacol | 2018 |
| 27265891 | Return of the lysergamides. Part II: Analytical and behavioural characterization of N<sup>6</sup> -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ). | Drug Test Anal | 2017 |
| 28129538 | Crystal Structure of an LSD-Bound Human Serotonin Receptor. | Cell | 2017 |
| 28500275 | Experimental evaluation of the generalized vibrational theory of G protein-coupled receptor activation. | Proc Natl Acad Sci U S A | 2017 |
| 28342178 | Return of the lysergamides. Part III: Analytical characterization of N[6] -ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1-propionyl ETH-LAD (1P-ETH-LAD). | Drug Test Anal | 2017 |
| 28143767 | Striatal dopamine D1 receptor suppression impairs reward-associative learning. | Behav Brain Res | 2017 |
| 28947075 | Psychedelic Drugs in Biomedicine. | Trends Pharmacol Sci | 2017 |
| 28019026 | Psychedelics as Medicines: An Emerging New Paradigm. | Clin Pharmacol Ther | 2017 |
| 26841800 | Psychedelics. | Pharmacol Rev | 2016 |
| 26340558 | Comparison of electrospray ionization and atmospheric pressure photoionization liquid chromatography mass spectrometry methods for analysis of ergot alkaloids from endophyte-infected sleepygrass (Achnatherum robustum). | J Pharm Biomed Anal | 2016 |
| 27071089 | Neural correlates of the LSD experience revealed by multimodal neuroimaging. | Proc Natl Acad Sci U S A | 2016 |
| 25320048 | The G protein-biased κ-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo. | J Pharmacol Exp Ther | 2015 |
| 26212274 | Analytical characterization of bioactive N-benzyl-substituted phenethylamines and 5-methoxytryptamines. | Rapid Commun Mass Spectrom | 2015 |
| 25909758 | Neuroreceptor activation by vibration-assisted tunneling. | Sci Rep | 2015 |
| 25547199 | N-Benzyl-5-methoxytryptamines as Potent Serotonin 5-HT2 Receptor Family Agonists and Comparison with a Series of Phenethylamine Analogues. | ACS Chem Neurosci | 2015 |
| 24704148 | Chronic LSD alters gene expression profiles in the mPFC relevant to schizophrenia. | Neuropharmacology | 2014 |
| 24830182 | The Heffter Research Institute: past and hopeful future. | J Psychoactive Drugs | 2014 |
| 23336049 | Extensive rigid analogue design maps the binding conformation of potent N-benzylphenethylamine 5-HT2A serotonin receptor agonist ligands. | ACS Chem Neurosci | 2013 |
| 24149187 | New victims of current drug laws. | Nat Rev Neurosci | 2013 |
| 23756634 | Effects of Schedule I drug laws on neuroscience research and treatment innovation. | Nat Rev Neurosci | 2013 |
| 22176338 | A reported "new synthesis of lysergic acid" yields only the derailment product: methyl 5-methoxy-4,5-dihydroindolo[4,3-f,g]quinoline-9-carboxylate. | Org Lett | 2012 |
| 23209503 | trans-2-(2,5-Dimethoxy-4-iodophenyl)cyclopropylamine and trans-2-(2,5-dimethoxy-4-bromophenyl)cyclopropylamine as potent agonists for the 5-HT(2) receptor family. | Beilstein J Org Chem | 2012 |
| 23018094 | Identification of a 2-phenyl-substituted octahydrobenzo[f]quinoline as a dopamine Dâ¿¿ receptor-selective full agonist ligand. | Bioorg Med Chem | 2012 |
| 22222862 | Comparison of the Dâ¿ dopamine full agonists, dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's disease. | Psychopharmacology (Berl) | 2012 |
| 22222861 | Behavioral effects of α,α,β,β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor. | Psychopharmacology (Berl) | 2012 |
| 22334593 | Ligand-specific roles for transmembrane 5 serine residues in the binding and efficacy of dopamine D(1) receptor catechol agonists. | Mol Pharmacol | 2012 |
| 22204903 | Analogues of doxanthrine reveal differences between the dopamine D1 receptor binding properties of chromanoisoquinolines and hexahydrobenzo[a]phenanthridines. | Eur J Med Chem | 2012 |
| 21209630 | Legal highs: the dark side of medicinal chemistry. | Nature | 2011 |
| 21862338 | Assessment of dopamine Dâ¿ receptor affinity and efficacy of three tetracyclic conformationally-restricted analogs of SKF38393. | Bioorg Med Chem | 2011 |
| 21827831 | A 5-HT(2C) receptor antagonist potentiates a low dose amphetamine-induced conditioned place preference. | Neurosci Lett | 2011 |